PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 23, 2024Current Medical Research and Opinion10 citationsOpen Access

Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers

View Full Paper
CSCarolina SchinkeBDBinod DhakalSMSandra Mazzoni

Key Points

Key points are not available for this paper at this time.

Abstract

Objective Talquetamab is the first-in-class GPRC5DxCD3 bispecific antibody for relapsed/refractory multiple myeloma. Given limited real-world data, this study was conducted with US healthcare providers (HCPs) to understand real-world talquetamab dosing and symptom management.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schinke et al. (2024) studied this question.

synapsesocial.com/papers/68e5b277b6db64358754b35ahttps://doi.org/10.1080/03007995.2024.2387183
Ask AI
Helpful
Bookmark
Share
View Full Paper